With yet a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA), the field is beginning to show progress in the fight to slow the disease.
Surveillance Still Not an Option for Many With Subsegmental Pulmonary Embolism
Only a narrow pool of outpatients with acute subsegmental pulmonary embolism (PE) may be candidates for structured surveillance without anticoagulation based on current guideline restrictions,
August 4, 2023